Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
    Journal Article

    Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Lia Palomba, M.; Drullinsky, P. R.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Elstrom, R.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control
    Meeting Abstract

    Seymour, J. F.; Davids, M. S.; Pagel, J. M.; Kahl, B. S.; Wierda, W. G.; Puvvada, S.; Gerecitano, J. F.; Kipps, T. J.; Anderson, M. A.; Huang, D. C. S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Meeting Abstract

    Mau-Soerensen, M.; Razak, A. R. A.; Shields, A. F.; Gabrail, N. Y.; Gerecitano, J. F.; Shacham, S.; Lassen, U. N.; Rashal, T.; Cooksoy, J.; Landosman, Y.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin I (XPOI) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa)
    Meeting Abstract

    Martignetti, J.; Razak, A. R. A.; Chen, Y.; Gabrail, N. Y.; Gerecitano, J. F.; Camacho, C.; Pereira, E.; Dottino, P. R.; Shacham, S.; McCauley, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas
    Meeting Abstract

    Infante, J. R.; Shapiro, G.; Witteveen, P.; Gerecitano, J. F.; Ribrag, V.; Chugh, R.; Issa, I.; Chakraborty, A.; Matano, A.; Zhao, X. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses
    Meeting Abstract

    Davids, M. S.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Pagel, J. M.; Wierda, W. G.; Anderson, M. A.; Rudersdorf, N.; Gressick, L. A.; Montalvo, N. P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save